Praluent® (alirocumab) – ODYSSEY Outcomes study results
March 10, 2018 - Regeneron and Sanofi announced that a clinical study demonstrated that Praluent (alirocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event.
Top